HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use ONDANSETRON safely and effectively. See full prescribing information for ONDANSETRON. ONDANSETRON injection, for intravenous or intramuscular use Initial U.S. Approval: 1991 RECENT MAJOR CHANGES
INDICATIONS AND USAGEDOSAGE AND ADMINISTRATIONPrevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy (2.1):
Prevention of Postoperative Nausea and/or Vomiting (2.2):
Patients With Severe Hepatic Impairment (2.3):
DOSAGE FORMS AND STRENGTHSInjection: 2 mL single-dose vial and 20 mL multiple-dose vial. (3) CONTRAINDICATIONSWARNINGS AND PRECAUTIONS
ADVERSE REACTIONSChemotherapy-Induced Nausea and Vomiting:
Postoperative Nausea and/or Vomiting:
To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION. Revised: 1/2022 |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
ondansetron injection, USP - VIAL Highlights
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at(800) 438-1985.
(800)-332-1088.